Penn State Hershey Medical Center home Penn State Hershey Medical Center home Penn State Hershey: Patient Care home Penn State Hershey: Education home Penn State Hershey: Research home Penn State Hershey: Community home
Penn State Hershey Health Information Library
  Library Home
  Find A Physician
  Find A Practice
  Request An Appointment
  Search Clinical Studies
  Classes and Support Groups
  Ask A Health Librarian
  Subscribe to eNewsletters


Penn State Hershey Health Information Centers
  Bone and Joint
  Cancer
  Children
  Heart
  Men
  Neurology
  Pregnancy
  Seniors
  Women

        Follow Us

New Treatment Approved for Opioid Dependence

MONDAY, Sept. 10, 2018 (HealthDay News) -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the agency said in a news release.

Both buprenorphine and naloxone have been approved previously for this purpose.

"Opioid replacement therapy can be an important part of effective treatment," said FDA Commissioner Dr. Scott Gottlieb. "Opioid use disorder should be viewed similarly to any other chronic condition that is treated with medication."

The newly approved drug duo should be part of a complete treatment plan that includes counseling and psychosocial support to treat people with opioid use disorder. Cassipa may only be dispensed by approved prescribers, the agency said.

Side effects of the drugs include oral numbness, burning mouth, inflammation of the mouth's mucous membrane, headache, nausea, vomiting, excessive sweating and constipation.

Cassipa is produced by Teva Pharmaceuticals USA, based in New Jersey. Its parent company is located in Israel.

More information

Visit the U.S. Food and Drug Administration.



-- Scott Roberts

Copyright © 2018 HealthDay. All rights reserved.